Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Thoracic 1

Conditions

Multiple Myeloma 2Recurrence 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Fumigant 93 × 1 year × Clear all
NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Not yet recruiting
255 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02504489 2026-05-19

DUBLIN-3

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed
559 enrolled 32 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05900882 2025-08-17

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
35 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡